EligibleTrials
Drugs & treatments › VMD-928 Tablet and Pembrolizumab (200 mg)

VMD-928 Tablet and Pembrolizumab (200 mg): clinical trials recruiting now

Fewer than 3 recruiting trials found.

1
Recruiting trials
15
Conditions studied
11
US states with sites
2
Countries

Phase breakdown

Phase 1 1 Phase 2 1

Conditions being studied

ConditionTrials
Adenoid Cystic Carcinoma1
Any Solid Tumors Progressed After a Prior Immunotherapy1
Esophageal Cancer1
Head and Neck Cancers1
Head and Neck Cancers - Nasopharyngeal1
Head and Neck Cancers - Salivary Gland1
Head and Neck Cancers - Throat1
Head and Neck Cancers - Tonsils1
Head and Neck Cancers Hypopharynx1
Head and Neck Cancers Larynx1
Head and Neck Cancers Lip1
Head and Neck Cancers Nasopharynx1
Head and Neck Cancers Oral Cavity1
Head and Neck Cancers Oropharynx1
Head and Neck Cancers Trachea1

Recruiting trials involving VMD-928 Tablet and Pembrolizumab (200 mg)

Common questions

How many recruiting trials involve VMD-928 Tablet and Pembrolizumab (200 mg)?

1 recruiting trial across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.